PULMONARY SURFACTANT PROTEIN-D IN SERA AND BRONCHOALVEOLAR LAVAGE FLUIDS
PULMONARY SURFACTANT PROTEIN-D IN SERA AND BRONCHOALVEOLAR LAVAGE FLUIDS
复制标题
DOI：
10.1164/ajrccm.152.6.8520747
复制
发表时间：
1995-12-01
影响因子：
24.7
通讯作者：
ABE, S
中科院分区：
文献类型：
--
作者：
HONDA, Y;KUROKI, Y;ABE, S
肺表面活性蛋白D（SP-D）是一种亲水性糖蛋白，分子量约为43 kDa，与甘露糖结合蛋白、肺表面活性蛋白A（SP-A）等沿着为C型凝集素超家族成员。我们最近制备了抗人SP-D的单克隆抗体，并建立了酶联免疫吸附试验（ELISA）。本研究以人重组SP-D为标准品，采用ELISA法测定了肺部疾病患者血清和支气管肺泡灌洗液（BAL）中SP-D的水平。我们证明，在特发性肺纤维化（IPF）、间质性肺炎伴胶原病（IPCD）和肺泡蛋白沉积症（PAP）患者中，血清中SP-D浓度显著升高。IPF、IPCD和PAP患者的血清SP-D水平分别为健康志愿者的5.1倍、7.2倍和7.0倍; 91.5%的IPF患者、81.3%的IPCD患者和100%的PAP患者的血清SP-D水平超过临界值（平均值+对照值的2 SD）。血清SP-D水平似乎反映了IPF和IPCD的疾病活动性以及PAP的疾病严重程度。PAP患者的BAL液中SP-D水平较高，但IPF和IPCD患者则无。我们的结论是，测量血清中的SP-D可以提供一个容易识别的和有用的临床标记物，用于诊断IPF，IPCD和PAP，并可以预测IPF和IPCD的疾病活动性和PAP的疾病严重程度。
Pulmonary surfactant protein D (SP-D) is a hydrophilic glycoprotein with a reduced molecular mass of 43 kDa and a member of the C-type lectin superfamily, along with mannose-binding proteins and surfactant protein A (SP-A). We have recently prepared monoclonal antibodies against human SP-D and developed an enzyme-linked immunosorbent assay (ELISA). In this study, the levels of SP-D in sera and bronchoalveolar lavage (BAL) fluids of patients with lung diseases were determined by ELISA, using human recombinant SP-D as a standard. We demonstrated that the concentrations of SP-D in sera are prominently increased in patients with idiopathic pulmonary fibrosis (IPF), interstitial pneumonia with collagen disease (IPCD), and pulmonary alveolar proteinosis (PAP). Patients with IPF, IPCD, and PAP exhibited levels of serum SP-D 5.1-fold, 7.2-fold, and 7.0-fold, respectively, of those in healthy volunteers; 91.5% of the patients with IPF, 81.3% with IPCD, and 100% with PAP exhibited serum SP-D levels that exceeded the cut-off value (mean + 2 SD of control value). Serum SP-D levels appeared to reflect the disease activity of IPF and IPCD and the disease severity of PAP. High levels of SP-D in BAL fluids were shown in patients with PAP, but not with IPF and IPCD. We conclude that measurement of SP-D in sera can provide an easily identifiable and useful clinical marker for the diagnosis of IPF, IPCD, and PAP, and can predict the disease activity of IPF and IPCD and the disease severity of PAP.